New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 22, 2013
08:05 EDTTEVATeva says additional QNASL data to be presented at AAAAI meeting
Teva Pharmaceutical announced that additional data analyzed from the Phase III clinical program for QNASL Nasal Aerosol will be presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology in San Antonio, Texas on February 22-26. Data will be presented at the meeting regarding the efficacy of QNASL in treating the symptoms associated with seasonal and perennial allergic rhinitis, including the drug’s potential quality of life benefits and sleep quality improvement. Furthermore, the data also demonstrated nasal symptom relief in patients with SAR and PAR who received treatment with QNASL 24 hours after dosing. On March 23, 2012, the U.S. Food and Drug Administration approved QNASL. The product became available by prescription in April 2012.
News For TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
06:28 EDTTEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 14, 2014
11:23 EDTTEVABIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:19 EDTTEVATeva upgraded to Buy from Hold at Standpoint Research

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use